UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More
Clover Health launches chronic diseases-focused Clover Therapeutics
California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the ... Read More
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a ... Read More
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it ... Read More
FDA approves Genentech’s Ocrevus for multiple sclerosis treatment
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary of the Roche Group, for its multiple ... Read More